jnj-31020028

Description

Cross-References

ID Source	ID
PubMed CID	25134625
CHEMBL ID	1823342
SCHEMBL ID	1173864
MeSH ID	M0543769

Synonyms (32)

Synonym
jnj-31020028 ,
CHEMBL1823342 ,
bdbm50352371
1094873-14-9
unii-73f8xed6yp
n-(4-(4-((n,n-diethylcarbamoyl)(phenyl)methyl)piperazin-1-yl)-3-fluorophenyl)-2-(pyridin-3-yl)benzamide
73f8xed6yp ,
1-piperazineacetamide, n,n-diethyl-4-(2-fluoro-4-((2-(3-pyridinyl)benzoyl)amino)phenyl)-alpha-phenyl-
S6416
1-piperazineacetamide, n,n-diethyl-4-(2-fluoro-4-((2-(3-pyridinyl)benzoyl)amino)phenyl)-.alpha.-phenyl-
n-{4-[4-(diethylcarbamoyl-phenyl-methyl)-piperazin-1-yl]-3-fluoro-phenyl}-2-pyridin-3-yl-benzamide
(-)-n-{4-[4-(diethylcarbamoyl-phenyl-methyl)-piperazin-1-yl]-3-fluoro-phenyl}-2-pyridin-3-yl-benzamide
OVUNRYUVDVWTTE-UHFFFAOYSA-N ,
SCHEMBL1173864
CS-3499
HY-14450
jnj 31020028
jnj31020028
n-(4-(4-(2-(diethylamino)-2-oxo-1-phenylethyl)piperazin-1-yl)-3-fluorophenyl)-2-(pyridin-3-yl)benzamide
J-690028
AKOS026750301
EX-A712
n-(4-{4-[(diethylcarbamoyl)(phenyl)methyl]piperazin-1-yl}-3-fluorophenyl)-2-(pyridin-3-yl)benzamide
n-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide
mfcd18782744
n-[4-[4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl]-3-fluorophenyl]-2-pyridin-3-ylbenzamide
NCGC00390574-01
F15275
BCP14600
EX-A3333
Q27266173
AS-56367

Protein Targets (9)

Potency Measurements

Protein	Taxonomy	Measurement	Average (mM)	Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	4.2534	AID1645841
G	Vesicular stomatitis virus	Potency	9.5221	AID1645842
cytochrome P450 2D6	Homo sapiens (human)	Potency	18.9991	AID1645840
Interferon beta	Homo sapiens (human)	Potency	9.5221	AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	9.5221	AID1645842
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	9.5221	AID1645842
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	9.5221	AID1645842

Inhibition Measurements

Protein	Taxonomy	Measurement	Average (mM)	Bioassay(s)
Neuropeptide Y receptor type 2	Homo sapiens (human)	IC50	0.0060	AID1063861; AID616660
Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)	IC50	0.7100	AID758788

Bioassays (20)

Assay ID	Title	Year	Journal	Article
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 ISSN: 2472-5560	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 ISSN: 1091-6490	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 ISSN: 1091-6490	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5 ISSN: 1521-0111	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5 ISSN: 1521-0111	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1063837	Cmax in rat at 10 mg/kg, sc	2014	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2 ISSN: 1464-3405	Ligands of the neuropeptide Y Y2 receptor.
AID1063844	Selectivity ratio of NPYY4 receptor (unknown origin) to NPYY2 receptor (unknown origin)	2014	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2 ISSN: 1464-3405	Ligands of the neuropeptide Y Y2 receptor.
AID616660	Displacement of [125I]PYY from human NPY Y2 receptor expressed endogenously in KAN-Ts cells by scintillation counting	2011	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 21, Issue:18 ISSN: 1464-3405	The discovery and synthesis of JNJ 31020028, a small molecule antagonist of the Neuropeptide Y Y₂ receptor.
AID1063839	Oral bioavailability in rat at 10 mg/kg	2014	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2 ISSN: 1464-3405	Ligands of the neuropeptide Y Y2 receptor.
AID758787	Metabolic stability in rat liver microsomes assessed as compound remaining after 15 mins	2013	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14 ISSN: 1464-3405	The discovery of potent selective NPY Y(2) antagonists.
AID1063861	Displacement of [125I]-NPY from NPYY2 receptor (unknown origin)	2014	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2 ISSN: 1464-3405	Ligands of the neuropeptide Y Y2 receptor.
AID1063842	Selectivity ratio of NPYY5 receptor (unknown origin) to NPYY2 receptor (unknown origin)	2014	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2 ISSN: 1464-3405	Ligands of the neuropeptide Y Y2 receptor.
AID1063840	Bioavailability in rat at 10 mg/kg, sc	2014	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2 ISSN: 1464-3405	Ligands of the neuropeptide Y Y2 receptor.
AID1063841	Antagonist activity at NPYY2 receptor (unknown origin)	2014	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2 ISSN: 1464-3405	Ligands of the neuropeptide Y Y2 receptor.
AID1063845	In vivo occupancy of NPYY5 receptor in rat brain at 10 mg/kg, sc	2014	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2 ISSN: 1464-3405	Ligands of the neuropeptide Y Y2 receptor.
AID758788	Inhibition of MTP (unknown origin)	2013	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14 ISSN: 1464-3405	The discovery of potent selective NPY Y(2) antagonists.
AID758789	Metabolic stability in human liver microsomes assessed as compound remaining after 15 mins	2013	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14 ISSN: 1464-3405	The discovery of potent selective NPY Y(2) antagonists.
AID1063838	Half life in rat at 10 mg/kg, sc	2014	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2 ISSN: 1464-3405	Ligands of the neuropeptide Y Y2 receptor.
AID1063836	In vivo occupancy of NPYY5 receptor in sc dosed rat brain	2014	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2 ISSN: 1464-3405	Ligands of the neuropeptide Y Y2 receptor.
AID1063843	Selectivity ratio of NPYY1 receptor (unknown origin) to NPYY2 receptor (unknown origin)	2014	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2 ISSN: 1464-3405	Ligands of the neuropeptide Y Y2 receptor.

Research

Studies (19)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	15 (78.95)	24.3611
2020's	4 (21.05)	2.80

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (5.26%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	18 (94.74%)	84.16%

Substance	Studies	Classes	First Year	Last Year	Average Age	Relationship Strength	2010's
N-(4-ethoxyphenyl)-4-[hydroxy(diphenyl)methyl]-1-piperidinecarbothioamide	2	diarylmethane	2011	2014	11.5	high	2
2-(2-methoxyphenyl)-N-[4-[5-(3-methoxyphenyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide	1	oxadiazole; ring assembly	2014	2014	10.0	medium	1
3,5-dimethyl-4-[(4-methylphenyl)sulfonyl-phenylmethyl]isoxazole	1	sulfonic acid derivative	2014	2014	10.0	medium	1
jnj-5207787	2		2011	2014	11.5	high	2
neuropeptide y (24-36) amide, n-acetyl-(leu(28,31))-	1		2014	2014	10.0	medium	1

Substance	Studies	Classes	Roles	First Year	Last Year	Average Age	Relationship Strength	2000's	2010's	post-2020
pyridine	1	azaarene; mancude organic heteromonocyclic parent; monocyclic heteroarene; pyridines	environmental contaminant; NMR chemical shift reference compound	2021	2021	3.0	low	0	0	1
benzamide	1	benzamides		2021	2021	3.0	low	0	0	1
proglumide	1	benzamides; dicarboxylic acid monoamide; glutamine derivative; racemate	anti-ulcer drug; cholecystokinin antagonist; cholinergic antagonist; delta-opioid receptor agonist; drug metabolite; gastrointestinal drug; opioid analgesic; xenobiotic metabolite	2021	2021	3.0	low	0	0	1
corticosterone	2	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone	human metabolite; mouse metabolite	2010	2011	13.5	low	1	1	0
arginine	2	arginine; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	biomarker; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical	2012	2014	11.0	low	0	2	0
palladium	1	metal allergen; nickel group element atom; platinum group metal atom		2015	2015	9.0	low	0	1	0
deoxynivalenol	2	cyclic ketone; enone; primary alcohol; secondary alpha-hydroxy ketone; trichothecene; triol	mycotoxin	2013	2021	7.0	low	0	1	1
nicotine	1	3-(1-methylpyrrolidin-2-yl)pyridine	anxiolytic drug; biomarker; immunomodulator; mitogen; neurotoxin; nicotinic acetylcholine receptor agonist; peripheral nervous system drug; phytogenic insecticide; plant metabolite; psychotropic drug; teratogenic agent; xenobiotic	2011	2011	13.0	low	0	1	0
devazepide	1	1,4-benzodiazepinone; indolecarboxamide	antineoplastic agent; apoptosis inducer; cholecystokinin antagonist; gastrointestinal drug	2013	2013	11.0	low	0	1	0
raclopride	1	salicylamides		2015	2015	9.0	low	0	1	0
granisetron	1	aromatic amide; indazoles		2013	2013	11.0	low	0	1	0
biie 0246	2			2012	2014	11.0	low	0	2	0
cholecystokinin	1			2013	2013	11.0	low	0	1	0
neuropeptide y	4			2011	2018	10.2	medium	0	4	0
exendin (9-39)	1			2021	2021	3.0	low	0	0	1
olaparib	1	cyclopropanes; monofluorobenzenes; N-acylpiperazine; phthalazines	antineoplastic agent; apoptosis inducer; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor	2015	2015	9.0	low	0	1	0
peptide yy	2			2012	2013	11.5	low	0	2	0
cyclosporine	1			2014	2014	10.0	low	0	1	0
peptide yy	3			2010	2013	12.3	low	1	2	0

Condition	Studies	First Year	Last Year	Average Age	Relationship Strength	2000's	2010's	post-2020
Alcohol Abuse	2	2011	2014	11.5	low	0	2	0
Alcohol Drinking	2	2011	2014	11.5	low	0	2	0
Alcoholism	2	2011	2014	11.5	low	0	2	0
Anorexia	2	2010	2021	8.5	low	1	0	1
Anxiety	3	2010	2014	12.3	medium	1	2	0
Anxiety Disorders	1	2011	2011	13.0	low	0	1	0
Anxiety Neuroses	1	2011	2011	13.0	low	0	1	0
Congenital Zika Syndrome	1	2020	2020	4.0	low	0	1	0
Disease Models, Animal	4	2010	2020	10.5	medium	1	3	0
Drug Withdrawal Symptoms	2	2011	2011	13.0	low	0	2	0
Emesis	1	2013	2013	11.0	low	0	1	0
Recrudescence	1	2011	2011	13.0	low	0	1	0
Substance Withdrawal Syndrome	2	2011	2011	13.0	low	0	2	0
Vomiting	1	2013	2013	11.0	low	0	1	0
Zika Virus Infection	1	2020	2020	4.0	low	0	1	0

Long-term Use (1)

Article	Year
Chronic administration of the Y2 receptor antagonist, JNJ-31020028, induced anti-depressant like-behaviors in olfactory bulbectomized rat. Neuropeptides, , Volume: 46, Issue:6	2012

Bioavailability (1)

Article	Year
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular pharmacology, , Volume: 96, Issue:5	2019

jnj-31020028

Description

Cross-References

Synonyms (32)

Protein Targets (9)

Potency Measurements

Inhibition Measurements

Bioassays (20)

Research

Studies (19)

Study Types

Related Drugs (23)

Drugs Involved in Assays Together (5)

Drugs Researched Together (18)

Related Conditions (15)

Long-term Use (1)

Bioavailability (1)